Active clinical trials combining radiation, miscellaneous
| NCT Number | Phase | Title | Conditions | Interventions | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|---|
| Interleukin 2 | |||||||
| NCT02086721 | Phase 1 | Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor | Solid Tumour | L19-IL-2 (recombinant protein with IL-2) | SBRT, 7.5-30 Gy in 1-8 fx | 18 | Maastricht Radiation Oncology |
| NCT01416831 | Phase 2 | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. | Metastatic Melanoma | IL-2 | SBRT, 20 Gy × 1-2 fx | 44 | Providence Health & Services|Prometheus |
| NCT01896271 | Phase 2 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | Metastatic RCC, Melanoma | IL-2 | SBRT, 8-20 Gy in 1-3 fx | 26 | University of Texas Southwestern Medical Center|Prometheus |
| NCT01884961 | Phase 2 | Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 | Metastatic RCC, Melanoma | IL-2 | SBRT, 6-12 Gy × 3 fx | 19 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
| NCT02306954 | Phase 2 | Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer | Renal Cell Carcinoma | IL-2 | SBRT, 20 Gy × 2 fx | 84 | Providence Health & Services|Prometheus Laboratories |
| NCT02735850 | Phase 2 | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) | Stage IV NSCLC, Limited Metastatic Disease | L19-IL-2 | SBRT | 141 | Maastricht Radiation Oncology |
| Other Cytokines | |||||||
| NCT01973322 | Phase 2 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized “Proof-of-principle” Phase II Study (ABSIDE) | Metastatic Melanoma | IFN-alfa | IMRT, 8-12 Gy in 3 fx | 24 | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
| OX40 agonists | |||||||
| NCT01862900 | Phase 1|Phase 2 | Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy | Metastatic Breast Cancer | OX40 antibody (MEDI6469) | SBRT, 10-25 Gy in 1-2 fractions | 40 | Providence Health & Services |
| TLR agonists | |||||||
| NCT02180698 | Phase 1 | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery | Metastatic Sarcoma | TLR-4 agonist (GLA-SE) | RT, 5-6 fx over 2 wks | 18 | Fred Hutchinson Cancer Research Center |
| NCT02061449 | Phase 1 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | Cutaneous T-cell Lymphoma | TLR3 agonist Poly-ICLC | RT, 3 fx | 24 | New York University School of Medicine|Ludwig Institute for Cancer Research |
| NCT02254772 | Phase 1|Phase 2 | TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma | Recurrent Lymphoma | TLR-9 agonist (SD-101), Ipilimumab | local RT | 27 | Ronald Levy|National Cancer Institute (NCI)|Stanford University |
| NCT01421017 | Phase 1|Phase 2 | Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | Metastatic Breast Cancer | TLR-7 agonist Imiquimod, Cyclophosphamide | RT, 6 Gy × 5 fx | 55 | New York University School of Medicine|National Cancer Institute (NCI) |
| NCT01976585 | Phase 1|Phase 2 | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | Lymphoma | CDX-301, Poly-ICLC (TLR agonist) | Low dose RT | 30 | Joshua Brody|Icahn School of Medicine at Mount Sinai |
| Cancer Vaccines | |||||||
| NCT01436968 | Phase 3 | Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Prostate cancer | AdV-tk vs placebo, valacyclovir +/- ADT | EBRT, 8 wks | 711 | Advantagene |
| NCT02446093 | Phase 1|Phase 2 | Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma (PaTK02) | Pancreatic cancer | AdV-tk, mFOLFIRINOX, gemcitabine | EBRT | 44 | Ohio State University |
| NCT01833208 | Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T | Metastatic Prostate Cancer | Sipuleucel-T | High-dose 1 fx to bony metastasis | 15 | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Dendreon | |
| NCT01818986 | Phase 2 | Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) | Metastatic Prostate Cancer | Sipuleucel-T | SBRT, metastatic site | 41 | University of Texas Southwestern Medical Center |
| NCT02232230 | Phase 2 | A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T | Metastatic Prostate Cancer | Sipuleucel-T | RT, metastatic site | 100 | 21st Century Oncology|Dendreon |